Leukemia, Myeloid, Accelerated Phase
"Leukemia, Myeloid, Accelerated Phase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
| Descriptor ID |
D015465
|
| MeSH Number(s) |
C04.557.337.539.250.300 C15.378.190.636.370.300
|
| Concept/Terms |
Leukemia, Myeloid, Accelerated Phase- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myelogenous, Aggressive-Phase
- Leukemia, Myeloid, Accelerated-Phase
- Leukemia, Myeloid, Aggressive-Phase
- Myeloid Leukemia, Chronic, Aggressive-Phase
- Myelogenous Leukemia, Chronic, Aggressive-Phase
- Myeloid Leukemia, Chronic, Accelerated Phase
- Myeloid Leukemia, Chronic, Accelerated-Phase
- Myeloid Leukemia, Chronic, Aggressive Phase
- Leukemia, Myelogenous, Aggressive Phase
- Myelogenous Leukemia, Chronic, Aggressive Phase
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Accelerated Phase".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Leukemia, Myeloid, Accelerated Phase [C04.557.337.539.250.300]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Leukemia, Myeloid, Accelerated Phase [C15.378.190.636.370.300]
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Accelerated Phase".
This graph shows the total number of publications written about "Leukemia, Myeloid, Accelerated Phase" by people in this website by year, and whether "Leukemia, Myeloid, Accelerated Phase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 3 | 1 | 4 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 2 | 1 | 3 |
| 2015 | 4 | 0 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myeloid, Accelerated Phase" by people in Profiles.
-
Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol. 2023 09; 98(9):1350-1353.
-
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018 09 03; 8(9):88.
-
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322.
-
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017 10; 31(10):2065-2074.
-
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6.
-
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407.
-
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leuk Lymphoma. 2016; 57(3):654-65.
-
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6.
-
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904.
-
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15; 121(10):1637-44.